Articles

Poll

Podcasts

Slideshows

Videos

Rheumatology

Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.

The systematic review summarized the impact of biologics targeting the IL-23/Th17 axis.

Impact of IL-17/IL-23 Inhibitors on Subclinical Atherosclerosis in Patients With Plaque Psoriasis, PsA

The phase 3 DISCOVER-1 and DISCOVER-2 studies were used to evaluate dactylitis resolution in guselkumab-treated patients with psoriatic arthritis through 1 year. 

Guselkumab Treatment Linked to Dactylitis Resolution in Patients With Psoriatic Arthritis

Polypharmacy, defined as ≥5 concomitant drugs, was significantly higher in patients with psoriatic arthritis when compared with controls (49% vs 17%, respectively).

Polypharmacy is Significantly Higher in Patients with Psoriatic Arthritis

Results demonstrate that guselkumab was well-tolerated in studies continuing for 1 to 2 years among patients with active psoriatic arthritis regardless of TNFi experience.

Guselkumab Deemed Safe, Effective Treatment for TNFi-Experienced Patients with Psoriatic Arthritis 

Higher baseline Disease Activity Index for Psoriatic Arthritis (DAPSA) was associated with reduced probability of achieving low disease activity or remission. 

Apremilast Achieves Low Disease Activity, Remission in Real-World PsA Setting

New pooled data from DISCOVER-1 and DISCOVER-2 show the injection biologic provided full resolution of dactylitis in three-fourths of patients by week 52.

Guselkumab Resolves Most Psoriatic Arthritis Dactylitis at 1 Year

A cohort analysis from Norway suggests women with active psoriatic arthritis or  axial spondylitis are at greater risk of either elective or emergency delivery procedures.

Psoriatic Arthritis Linked to Increased Risk of Emergency Caesarean Sections

Radiographic non-progressors treated with guselkumab achieved patient-reported minimal disease activity criteria of minimal pain and normalized physical function more often than radiographic non-responders.

Low Disease Activity Linked to Less Radiographic Progression in Patients With PsA Receiving Guselkumab 

Study results are the first to demonstrate that tofacitinib may be an effective treatment option for Chinese patients with active psoriatic arthritis.

Tofacitinib Effective, Safe in Chinese Patients With Active Psoriatic Arthritis

Roy Fleischmann, MD, examined the necessity of performing repeated x-rays in patients with rheumatic disease as a part of disease management. 

Roy Fleischmann, MD: Are X-Rays Necessary for Treating Rheumatoid Arthritis and Psoriatic Arthritis?

On the HCPLive psoriatic arthritis page, resources on the topics of medical news and expert insight into PsA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on arthritis, and more.